On ECHEMI
Home > Drugs > Lymphocytic leukemia
Lymphocytic leukemia
There are two types of lymphocytic leukemia, one is acute lymphocytic leukemia and the other is chronic lymphocytic leukemia. Acute lymphocytic leukemia is a progressive malignant disease characterized by a large number of immature white blood cells similar to lymphoblasts. These cells can be found in the blood, bone marrow, lymph nodes, spleen and other organs. Chronic lymphocytic leukemia, referred to as CLL, is a malignant proliferative disease of lymphocytes in certain immune-deficient lymphocytes in the lymphocyte system with a slow onset. This disease is rare in my country, accounting for only 3.4% of leukemia, and is more common in Caucasians in Europe and America, accounting for 25-30%. The age of onset is mostly over 50 years old, and it is rare for those under 30 years old. There are more men than women. The main manifestations are systemic lymphadenopathy, splenomegaly, anemia and abnormal increase in lymphocytes in peripheral blood.
Related Drugs
Homoharringtonine
Indication: It is suitable for various types of acute non-lymphocytic leukemia, and also has certain therapeutic effects on myelodysplastic syndrome (MDS), chronic myeloid leukemia and polycythemia vera.
Homoharringtonine
Indication: It is suitable for various types of acute non-lymphocytic leukemia, and also has certain therapeutic effects on myelodysplastic syndrome (MDS), chronic myeloid leukemia and polycythemia vera.
Manufacturer:

Beijing Xiehe Pharmaceutical Co., Ltd.

Homoharringtonine Injection
Indication: It is suitable for various types of acute non-lymphocytic leukemia, and also has certain therapeutic effects on myelodysplastic syndrome (MDS), chronic myeloid leukemia and polycythemia vera.
Manufacturer:

Fuzhou FU Yao Pharmaceutical Co., Ltd.

Homoharringtonine Injection
Indication: It is suitable for various types of acute non-lymphocytic leukemia, and also has certain therapeutic effects on myelodysplastic syndrome (MDS), chronic myeloid leukemia and polycythemia vera.
Manufacturer:

Harbin Pharm. Group Sanjing Pharmaceutical Co., Ltd.

Fludarabine phosphate
Indication: For the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not improved or has progressed during or after treatment with at least one standard alkylating agent-containing regimen.
Manufacturer:

Chongqing Lummy LONG YU Pharmaceutical Co., Ltd.

Fludarabine phosphate
Indication: For the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not improved or has progressed during or after treatment with at least one standard alkylating agent-containing regimen.
Manufacturer:

Guangdong Lingnan Pharmaceutical Co., Ltd.

Fludarabine Phosphate for Injection
Indication: For the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not improved or has progressed during or after treatment with at least one standard alkylating agent-containing regimen.
Fludarabine Phosphate for Injection
Indication: For the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not improved or has progressed during or after treatment with at least one standard alkylating agent-containing regimen.
Manufacturer:

Shanxi PUDE Pharmaceutical Co., Ltd.

Asparaginase for injection
Indication: The remission rate of acute lymphocytic leukemia can reach more than 50%. It also has a certain effect on acute myeloid leukemia, acute monocytic leukemia and malignant lymphoma. It is often used in combination with vinblastine, prednisone, cytarabine, mercaptopurine, methotrexate, etc. to improve the efficacy and reduce the occurrence of drug resistance. Vincristine should be administered before asparaginase. If this product is given first, it will damage the liver's clearance of vincristine. The immunosuppressive effect of this product can also be used clinically to treat dermatomyositis.
Manufacturer:

Wuzhi Weierkang Biochemical Pharmaceutical Co., Ltd.

Asparaginase for injection
Indication: It is suitable for the treatment of acute lymphocytic leukemia (ALL), acute granulocytic leukemia, acute monocytic leukemia, chronic lymphocytic leukemia, Hodgkin's disease and non-Hodgkin's lymphoma, melanoma, etc. This product has an inhibitory effect on the proliferation of the above-mentioned tumor cells, and has the best effect on the induction remission of acute lymphoblastic leukemia in children. Sometimes it may also be effective for patients who relapse after remission with some commonly used chemotherapy drugs, but the remission period is short when used alone, and it is easy to produce drug resistance, so it is often used in combination with other chemotherapy drugs to improve the efficacy.
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.